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Abstract
For a long time, genetic studies of complex diseases were most
successfully conducted in animal models. However, the field of
genetics is now rapidly evolving, and human genetics has also
started to produce strong candidate genes for complex diseases.
This raises the question of how to continue gene-finding attempts
in animals and how to use animal models to enhance our
understanding of gene function. In this review we summarize the
uses and advantages of animal studies in identification of disease
susceptibility genes, focusing on rheumatoid arthritis. We are
convinced that animal genetics will remain a valuable tool for the
identification and investigation of pathways that lead to disease,
well into the future.
Introduction
The history of genome-wide mapping of disease-causing
genes began in 1980, when linkage analysis by use of anony-
mous genetic markers was suggested as a method for
conducting ‘forward genetics’ analyses (hypothesis-free map-
ping starting from a trait of interest) [1]. This soon led to
successful identification of several disease-causing genes,
often providing the first information on disease mechanisms.
In principal, there are two approaches to genetic mapping:
linkage and association analysis (reviewed in [2]). Linkage
analysis is based on inheritance of chromosomal fragments
within families with affected and unaffected individuals. It
allows genome-wide mapping with limited resources, but it
can generally only map loci into large genomic regions that
span hundreds of genes and, despite great success in
monogenic diseases, linkage analysis seems to be of limited
use in mapping of complex traits. Association studies com-
pare large unrelated groups of patients with the healthy
population to find regions that are overrepresented in patients.
This increases mapping precision dramatically but it requires
large repositories of patient materials and very closely spaced
genetic markers, creating a need for correction for multiple
testing, which raises the threshold for claiming statistical
significance. Until recently, candidate gene studies were the
only realistic way to utilize patient materials for association
studies. The major disadvantage of candidate studies is the
need for a starting hypothesis to choose candidates. The
most interesting prospect of gene mapping, however, is that
hypothesis-free mapping can point to previously unknown
and unexpected disease pathways.
Neither of these strategies has been successful in mapping
genes that control complex diseases, such as rheumatoid
arthritis (RA), in humans. Mapping in animal models therefore
emerged as an attractive alternative. Choosing candidates
identified by positional cloning in animal models combines
the high power of candidate studies with the benefits of
hypothesis-free mapping.
The traditional strategy to map genes in animals is to
intercross two inbred strains that differ in the trait of interest
for at least two generations, thereby allowing chromosome
regions to segregate, and permitting linkage analysis in a
setting with minimal genetic and environmental variation
(Figure 1). Not only is the mapping power superior to that in
human linkage analysis, but also the identified loci can be
isolated on a fixed genetic background to confirm the position
of the locus by backcrossing to one of the parental strains for
several generations to create a congenic strain (an inbred
strain with only a defined genetic region originating from
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another strain). The congenic region can then be minimized
by further backcrossing, checking each generation to make
sure that the quantitative trait locus (QTL) is still within the
congenic fragment, until only the causative gene remains.
As in the tale of the tortoise and the hare, human genetics has
been regarded as fast but unreliable, whereas animal genetics
is slow and laborious but likely to find the gene sooner or later.
However, even though a few victories have been won by the
tortoise, thanks to denser genotyping and considerably larger
patient cohorts that allow near genome-wide association
(GWA) mapping, human genetics has also started to produce
strong candidate genes for complex diseases. In light of this
success, we must consider how best to use animal models in
the future; is there still value in identifying the genes that affect
susceptibility to disease in these species as well?
Clearly, major challenges remain in human genetics that can
be resolved in animals. Most genes with medium or small
effects still need the focused and strategic work of animal
geneticists to reveal their secrets, and only animal genetics
studies allow controlled, repeated experiments that can
determine causality without doubt. Most important, however,
is that although human genetics often faces dead ends
because the function of the identified gene is unknown,
animal models allow us to investigate the role played by the
genes and to perform conclusive experiments to investigate
disease mechanisms and develop more precise treatments.
Current status of human genetics research
The advent of GWA in humans ushered in a new era in
disease genetics. GWA studies have been very successful in
identifying with statistical rigour the genes that are
responsible for several complex diseases, including arthritis,
which is reviewed in detail in other articles in this series (for
another review, also see [3]). However, at this stage the
human GWA studies still wrestle with severe problems and
limitations; this is particularly apparent in arthritis studies,
where success has been more moderate than for many other
complex diseases.
Figure 1
Strategies in animal models. Presented are the most common strategies employed to identify and validate a candidate gene using animal models.
GWA, genome-wide association; QTL, quantitative trait locus.The major problem is the strict correction for multiple testing
needed to exclude false positives after performing hundreds
of thousands, or even millions, of tests. It is therefore
estimated that materials from tens of thousands of patients
and control individuals are needed to identify the majority of
genetic effects [4]. Studies combined with retesting in other
materials is likely to allow confirmation of the strongest of
these associations in the near future, but most are likely to
elude mapping. This will be especially true for diseases such
as RA, for which studies thus far suggest that the patient
population must be stratified into smaller patient groups,
resulting in smaller bodies of patient materials and even larger
numbers of tests [5,6]. This problem will be even worse if
interactions are to be addressed. This is an important issue
because it is likely that much of the genetic influence is
through patterns of interacting genes.
Another issue is the limited possibilities for follow-up
experiments in humans. Many loci found by association
mapping are located in intergenic regions, including two of
the strongest loci for RA, namely TRAF1-C5 and TNFAIP3-
OLIG3, making it difficult to establish causality [7,8]. TRAF1
and TNFAIP3 have been favoured as candidates based on
previous knowledge of their function in tumour necrosis factor
signalling [9,10], which is known to be important in RA
(reviewed in [11]). Although it is likely that these genes truly
are involved in the pathogenesis of RA, this remains to be
proven; as for candidate studies, this type of reasoning is
counter to one of the main aims: hypothesis-free generation of
new knowledge. Interestingly, C5 has already been implicated,
based on studies conducted in mice [12-14], and it should
therefore be considered an equally likely candidate. Similar
problems have been apparent for half a century in elucidating
the major histocompatibility complex (MHC) region, in which
the genes may operate as linked units, haplotypes. More
precise phenotypic information and biological knowledge is
needed to understand these genetic regions.
Animal models and their relevance to
rheumatoid arthritis
The value of mapping in animals is dependent on there being
good models of human diseases. In this review we focus on
RA, a highly heterogeneous autoimmune disease that is
known to depend on multiple genes and environmental
factors. The disease models should therefore preferably be
correspondingly polygenic and dependent on environment.
There are a number of available animal models for RA that all
mimic various aspects of the disease, possibly reflecting
disease pathways that operate in different subgroups of RA
patients. Thus, all of these models can be valuable under
certain conditions, depending on the question that is to be
addressed.
Induced arthritis models
If an antigen is known to induce disease, then this permits
studies of the antigen-specific response and allows mapping
of the genes involved. Collagen-induced arthritis (CIA) is
induced by the major collagen found in cartilage, namely
collagen type II (CII), emulsified in adjuvant [15,16]. Disease
develops 2 to 3 weeks after immunization in susceptible
strains (H-2q or H-2r) [17]. CIA is the most widely used model
for studying arthritis pathology and for testing for novel anti-
inflammatory therapeutics [18].
Proteoglycan (aggrecan)-induced arthritis (PGIA), character-
ized by a progressive disease course, is induced by cartilage
proteoglycans. PGIA presents with 100% incidence in
BALB/c mice (H-2d), which are normally resistant to CIA [19],
and manifest in substrains of C3H (H-2k) [20]. CIA and PGIA
are the two most commonly used RA models for QTL
mapping in mice. Both models are complex highly polygenic
diseases that are dependent on both B and T cells [21-24]
and are both associated with MHC class II molecules
(MHCII) and a large number of both common and unique
non-MHC loci (Figure 2) [17,25]. Both CIA and PGIA are
believed to have relevance to human disease because
antibodies to both CII and proteoglycan in RA patients have
been identified [26-28].
Other cartilage structures that can induce arthritis include
cartilage oligomeric matrix protein [29,30] and type XI
collagen [31].
Collagen antibody-induced arthritis (CAIA) is induced by
injection of specific monoclonal CII antibodies [32]. The
model was developed based on the finding that serum from
arthritic mice or RA patients could transfer arthritis to naïve
mice [33,34]. CAIA resembles CIA but is more acute and has
a rapid onset, a few days after injection. Normally, the disease
heals after a month and mice remain healthy. The CAIA model
is unique because it is independent of MHC and T and B
cells [35,36]. Instead, neutrophils and macrophages are
recruited and activated independent of the adaptive immune
system, as a result of antibodies binding to the cartilage
surface and fixing complement [36]. This allows investigation of
effector mechanisms without involvement of the priming phase.
A number of bacteria also have the capacity to induce
arthritis in animals. Mice infected with Borrelia develop a
disease similar to RA (B. burgdorferi associated arthritis) [37]
and Staphyolococcus aureus causes septic arthritis in both
rats and mice [38,39]. Bacterial components, such as cell
wall fragments, DNA and heat shock proteins, can also
induce arthritis by themselves, one example being the
streptococcal cell wall induced arthritis model [40]. In rats,
exposure to heat-killed Mycobacterium tuberculosis in adju-
vant results in Mycobacterium induced-arthritis, often referred
to as adjuvant-induced arthritis [41]. This model was
developed in 1947 when it was found that a mixture of
mineral oils, emulsifier and mycobacteria - namely complete
Freund’s adjuvant - was a potent immunological adjuvant. It
was later found that a similar mixture but excluding myco-
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genic capacity (oil-induced arthritis) [42]. In addition, some
mineral oils by themselves had the capacity to induce arthritis,
including squalene [43] and pristane [44].
Pristane-induced arthritis (PIA) in rats highly resembles many
aspects of the human disease because it is chronic, sym-
metrical, and serum rheumatoid factor is present and radio-
graphic changes are apparent [44,45]. Even though pristane
does not contain peptides that could bind to MHC, PIA has
been shown to be T-cell driven and dependent on MHCII
[46], suggesting that the arthritogenic T cells recognize a
self-antigen on the MHC complex, but thus far no such
antigen has been identified.
Genetically altered mice as models of arthritis
There are also animal models that are produced using
transgenic techniques, and develop arthritis spontaneously,
which can be used to map modifier genes. Examples are IL-1
receptor antagonist knockouts, IL-1 over-expressing mice,
gp130 knock-ins and human tumour necrosis factor-α trans-
genic mice [47-50]. K/B×N mice express a transgenic T-cell
receptor (KRN) and the NOD-derived Ag7 MHCII allele, and
develop severe arthritis spontaneously [51]. The autoantigen
is the ubiquitously expressed enzyme glucose-6-phosphate
isomerase [52], but inflammation is restricted to the joints,
and the disease exhibits many of the characteristics of human
RA. Autoantibodies play a pathogenic role in this model,
because arthritis can be transferred to a wide range of
recipients with serum from K/B×N mice (serum transfer-
induced arthritis) [53]. Arthritis can also be induced by
injection of recombinant glucose-6-phosphate isomerase in
mice [54].
In addition, there are spontaneous models that develop
arthritis because of a single mutation. These models can be
derived as a result of a spontaneous mutation or following N-
ethyl-N-nitrosurea mutagenesis. The causative mutation can
then be positionally cloned by means of linkage analysis
(Figure 1).
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Figure 2
Overview of CIA, PGIA and STIA loci mapped in mouse. CIA, collagen-induced arthritis; PGIA, proteoglycan (aggrecan)-induced arthritis; STIA,
serum transfer-induced arthritis.Genetic modifications of animals
With emerging knowledge of the major genes that underlie
human disease and improved animal models, it seems
straightforward to investigate the in vivo function of these
genes in the animal models. To this end, the particular genes
can be humanized or modified in mice and the effect of the
specific mutations on disease development investigated
(Figure 1). Of particular use will be new technologies to
modify the genome, which will allow researchers to introduce
genes, mutate genes in specific tissues and express proteins
flagged with various markers. There are, however, some
significant drawbacks that have thus far limited the use of this
technology, and these need to be highlighted. First, it is
essential that the modifications are dependent on the genetic
context (the new genetic modifications will interact with other
genes in the genome, specifically mouse genes). Second, to
conduct conclusive experiments and compare them between
different laboratories, the genetic background must be inbred
and standardized. Finally, modifications to the genome lead to
artifacts that interfere with interpretation of the results.
Clearly, to use genetic modifiactions we must obtain better
knowledge about the genomic control of the disease in
question in mice. We first discuss some of the problems that
genetic modifications may cause.
Although transgenic or genetic knockout strategies are
appealing, being relatively fast and cost efficient, it is
important to appreciate that they carry a high risk of
artifacts. Despite the efficiency of inserting a mutation that
completely disrupts the function of a gene, most genetic
factors in common complex diseases are expected to be
noncrucial, coding single nucleotide polymorphisms or
expression differences [55]. Complete elimination of a gene
does not necessarily have the same effect as a smaller
change that affects, for instance, expression kinetics or
binding to a target molecule. Accordingly, studies of
knockout mice have identified phenotypes that are
fundamentally different from what was expected from the
naturally occurring locus. This is clearly seen in the case of
the Ncf1 gene. Mice with a spontaneous mutation in this
gene, resulting in a truncated protein, exhibit increased
susceptibility to models of arthritis and even develop
arthritis spontaneously [56], whereas knockout of Ncf1
results in chronic granulomatous disease with severe
infections as a consequence [57]. The same problems
apply to other types of transgenes in which a construct is
expressed outside its normal context, possibly with dramatic
effects on gene regulation and protein expression. This can
also be true in humanized mice, in which human genetic
variants have been introduced in an artificial genetic
interactive environment. Nevertheless, these mice can be
extremely useful in clarifying specific questions. For
example, humanized mice have successfully been used to
investigate the individual roles of MHC class II molecules
(MHCII) in arthritis and were proven to be useful in
identifying T-cell epitopes (reviewed in [58]).
Another important issue when studying polygenic diseases is
that transgenics can normally not be made directly in the
strain that will be used for experiments. Transgenic mice are
instead made in embryonic stem cells, usually from the 129
or C57BL/6 strains, and backcrossed to the strain of interest,
thus creating a mixed genome with a 129 or C57BL/6 region
surrounding the insert. Even after 10 generations of
backcrossing, there is almost 40% risk that a locus 10 cM
from the targeted gene is still within this fragment, a region
that could contain hundreds of genes [59]. Based on findings
from mappings of CIA in mouse, it is quite likely that this
congenic fragment will contain QTLs that affect the trait,
making it impossible to know whether the phenotype truly
originates from the transgene (Figure 2) [60-62].
Such linked QTLs have proven to be a problem in several
studies. For example, the osteopontin (Opn) gene was sug-
gested to be involved in autoimmunity based on pheno-
typing of a knockout strain, but it was later revealed that
another Opn knockout had no such phenotype, and that the
effect was probably due to liked genes in the 129 fragment
[63]. More recently, contradictory data about the role of
IL-21 in autoimmunity and differentiation of T-helper-17
cells have led to a similar discussion. In fact, none of the
studies using IL-21 or IL-21 receptor knockout mice were
set up such that the influence of other genes could be
excluded [64]. This is especially problematic if the aim is to
confirm the mapping of a candidate gene. Random insertion
may affect the usage of the gene whereas targeted insertion
will place it within a congenic region that might contain the
QTL studied, yielding false-positive confirmation (Figure 1).
Most importantly, there is a risk that only hypothesis-
confirming results will be reported, without any correction
for multiple testing.
Gene findings in animal models
Linkage analysis of segregating crosses between inbred
strains with different susceptibilities to arthritis has proven to
be very efficient and informative. It has confirmed
polygenicity and shown that some, but not all, loci are
shared between models and strain combinations. Figure 2
shows loci controlling CIA (40 loci) and PGIA (29 loci) in
mice [65]. The majority of these loci were mapped in
genome-wide F2 crosses. However, parts of chromosomes
3, 6, 7, 14 and 15 have been fine mapped in partial
advanced intercrosses and subcongenic strains, and in all
regions studied loci have appeared where nothing was
detectable in F2 crosses, suggesting that the locus density
could be as high on all chromosomes [60-62,66]. Similar
numbers of loci have been mapped in rat models of arthritis:
29 for CIA, 39 for PIA, eight for oil-induced arthritis and five
controlling adjuvant-induced arthritis [67]. These fine-
mapping studies suggest that multiple arthritis loci on a
chromosome is the rule rather than the exception; it is
especially important to bear this in mind when designing
experiments in genetically modified strains.
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study of gene-gene interactions. Studying interactions is
statistically challenging because of the enormous number of
tests that must be conducted. Animal crosses allow mapping
and modelling of multiple locus interactions, which has turned
out to be of fundamental importance in some phenotypes.
The Cia21 and Cia22 loci increase susceptibility to arthritis
in mice only in the presence of RIIIS/J alleles in the Cia32
locus, which also interacts with Cia31 and  Cia26 [61].
Including interactions in the analysis has also allowed
mapping of several other loci, including Cia41 and Cia42 in
mouse and Cia26 in rats [60,68]. Performing this type of
study in humans would require even larger patient
populations and computation resources, and will remain
unfeasible for many years yet.
Positioning of the underlying genes has, as expected, not
been achieved with similar ease. Initial expectations of rapid
gene identification have been based on an underestimation of
the complexity of the disease, even if it is bound to be less
extensive than in the human situation. Another problem has
been to find relevant recombinations that split the strongly
linked genetic fragments controlling disease. The genetic
effect may in fact be dependent on haplotypes rather than on
single genetic polymorphisms. In spite of this, a number of
genes - for example, MHCII [17,69,70], Ncf1 [56,71] and Hc
(C5) [12-14] - have been successfully identified as arthritis
regulating using animal models. Furthermore, the Oia2 locus
in rats has been shown to be caused by variation in a gene
complex encoding C-type lectin-like receptors (APLEC), but
thus far it has not been possible to establish which of the
genes is responsible for the effect [72].
The MHCII region was the first locus found to be associated
with arthritis in both mice [17,69] and humans [73], and it
remains the strongest association in both species. It was
recognized early on that CIA susceptibility was almost
exclusively seen in inbred strains that had either H2q or H2r
haplotype at the MHC locus [17,69]. The H2p protein, which
renders mice nonsusceptible to CIA, differs from H2q only by
four amino acids in the peptide binding groove, and changing
these to the corresponding amino acids in the H2q sequence
makes the H2p mice susceptible to CIA [70]. Interestingly,
the binding groove of the H2q MHC strongly resembles that
of the human HLA-DRB1*04 and *01 shared epitope haplo-
types, which are associated with increased risk for develop-
ment of RA. Furthermore, transgenic mice expressing the
human risk haplotypes are susceptible to CIA [74].
The C5 gene is a very strong candidate gene for the Cia2
locus, which has been identified in two different F2 crosses,
including the NOD.Q and SWR/J strains [12,13]. It has also
been confirmed in an advanced intercross and in congenic
lines, although in these situations there is evidence for
additional contributing genetic influences closely linked to C5
[14]. These strains are C5 deficient because of frame shift
deletion and early termination of translation [75]. The C5
polymorphism is not found in wild mice, however, although it
is widespread in inbred strain, possibly because of a
bottleneck effect during domestication. The suspected role of
C5 and complement in RA has been confirmed in numerous
animal experiments and models (reviewed in [76]).
Importance in humans has been suggested by increased
complement activity in RA joints compared with joints
afflicted with other arthritides [77,78] and was also
supported by the TRAF1-C5 association [7].
The Ncf1 gene, which encodes the p47phox protein of the
phagocytic NADPH (nicotinamide adenine dinucleotide
phosphate) oxidase complex, has been positionally cloned as
the major gene underlying the Pia4 locus in rats. Surprisingly,
the mutation - resulting in low production of reactive oxygen
species (ROS) - rendered the animals more susceptible to
severe arthritis [71] as a result of altered oxidation status of
arthritogenic T cells [79]. This finding was reproduced in a
mouse strain carrying another spontaneous mutation in Ncf1
and with nearly absent ROS production [56,80]. Based on
knowledge from the animal studies, we conducted a
candidate association study in a human case-control study of
RA. Because NCF1 is more complex in human than in
mouse, with pseudogenes and copy number variations
[81,82], we limited our study to the other subunits of the
NADPH oxidase complex. We hypothesized that single
nucleotide polymorphisms in any of the other subunits could
cause the same reduction in ROS production and thereby
affect disease. Accordingly, we found an association with
NCF4 (p40phox) in rheumatoid factor negative men [82].
This proves that although not all genetic findings in animals
can be directly translated to humans, we can identify
pathways in mice that are likely to operate similarly in humans.
A success story for mapping of spontaneous mutations is the
SKG mouse, derived from a BALB/c breeding. The SKG
mouse strain develops severe chronic arthritis at around 8
weeks of age, because of a mutation in the ZAP70 gene. The
SKG model presents with high titres of rheumatoid factor and
anti-CII autoantibodies, suggesting that it resembles RA both
clinically and serologically [83]. ZAP70 is a key signal
transduction molecule in T cells [83,84] and the mutation
alters sensitivity to thymic selection, resulting in positive
selection of otherwise negatively selected autoimmune cells.
Interestingly, even though autoreactive T cells are present in
the periphery, an infectious agent is necessary for disease
development [85].
The future of animal genetics
Like genetics research in humans, that in animals has
progressed in recent years. A wealth of resources has been
developed as a result of collaborative efforts, including
bioinformatics tools, sequence and expression databases,
and designer animals (for an extensive review of available
resources, see [86]). New mouse resources, such as outbred
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facilitate QTL mapping, and the first studies have reported
breathtaking results on the number of QTLs and interactions
between genes and environment [87,88].
Outbred strains have high-density recombinations that can
allow mapping to subcentimorgan levels in one generation, by
combining the advantages of association mapping with the
power of mapping in animal models. One such resource is
heterogeneous stocks, in which several founder strains have
been intercrossed for numerous generations, resulting in a
fine mosaic of founder strain haplotypes [89,90]. The known
ancestry of the alleles increases mapping power compared
with natural populations. Furthermore, compared with
crosses of only two strains, heterogeneous stocks mice also
have a large number of alleles, making it more probable that a
QTL segregates in the cross. A number of genes and loci
controlling other complex traits have already been mapped in
outbred stocks, and studies on arthritis in both mice and rats
are on the way [87,91,92].
Another resource that is under development, the
collaborative cross, can make the process even more
efficient by minimizing the cost of genotyping. By creating
1,000 recombinant inbred lines from eight founder strains
that are first intercrossed to mix the genomes and then
inbred, a permanent resource of homozygous mice will be
generated that can be carefully genotyped once and then
used by research groups all over the world [93]. Production
of congenic strains for definite determination of causality will
be facilitated by starting from genome tagged or chromo-
somal substitution strains (inbred strains in which part of or
an entire chromosome has been exchanged for that of
another inbred strain by the same methods used for making
congenics) [94]. Large-scale projects are working at
generating transgenic mouse lines for all genes, which can
be used in confirmatory studies. Furthermore, the increasing
access to sequence information from more and more inbred
strains will facilitate the identification of causative poly-
morphisms and strengthen the power of in silico methods
for QTL analysis [86]. Unfortunately, the use of many of
these resources is limited by the strict MHC dependency of
most arthritis models.
Another interesting prospect is the use of microarray data, to
identify expression QTLs [95]. By considering gene expres-
sion levels as a quantitative trait, expression QTLs can be
mapped directly in crosses, both to identify candidate genes
and to indicate the key pathways affected. Of course, animal
models have a huge advantage compared with humans
because samples can be taken from any tissue or time point
in the disease course.
By combining these new resources, mapping in animals
could approach the speed of mapping in humans while
retaining the advantages of animal experiments.
Relevance of findings made in animal models
It is sometimes argued that findings made in animals are not
necessarily relevant to human disease. Naturally, there are
several major differences between human disease and animal
models. However, it is likely that the majority of genes will
operate in a similar way in humans as in animals. A gene
identified in animals might not be associated with disease in
humans (for example, because it is not polymorphic in the
human population), but it could still be part of a pathway that
operates similarly in both species, as in the case of NCF4.
This gene would not have been picked up by conventional
association studies, because the effect is weak and the
subpopulation small. However, thanks to the identification of
Ncf1 as a disease-regulating gene in rats and mice, we were
able to investigate a completely novel pathway in humans.
Even in the odd case in which the animal model operates
through completely different pathways than the human disease,
important information is gained, because animal models are
central to the development and testing of new therapeutic
strategies, and a discrepancy in disease mechanics can lead to
catastrophic consequences if the therapy is transferred to the
human situation after being proven safe and efficient in animals.
This was seen when an anti-CD28 monoclonal antibody
unexpectedly induced a life-threatening cytokine storm in
volunteers when taken to phase I trials, a tragedy that might
have been prevented by a better understanding of the immune
system of the model organisms [96].
Another difference is the effect of the environment. Animal
studies allow environmental factors to be limited to a minimum
by fixed living and eating conditions. Furthermore, the inducing
environmental factor is unknown in humans, whereas it is
defined in animal models. Although this facilitates
experimentation and increases power for the mapping, it can
also be limiting in that it excludes environmental factors, some
of which may be human specific, that can be pivotal in the
pathogenesis of human disease. For example, smoking has
been shown to play a role in susceptibility to arthritis and to
interact with genetic factors [97].
Conclusions
It is clear that both human and animal genetics have benefits:
human genetics in its certain relevance and relatively fast
identification procedure; and animal genetics in its ability to
limit complexity and so allow identification of loci with smaller
effects, its benefit of allowing conclusive confirmation of
findings, and its immense advantage in allowing further
investigation and manipulation of the genes and pathways
identified. In the same way, transgenic animals and congenic
strains have advantages and disadvantages that make them
more or less suited for each specific question considered.
Attempts to elucidate the tight nest of interacting genetic
effects that seem to make up the genetic background of truly
complex diseases such as RA will greatly benefit from a joint
attack along all avenues of research.
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competing options, but rather as complementary strategies
that, together, could provide a true understanding of the
genes and pathways that affect human diseases. They may
also permit improved understanding of the animal models that
we are so dependent on in the development of safe and
efficient drugs.
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